Core Laboratories (CLB) PT Raised to $21 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CLB Hot Sheet
Rating Summary:
9 Buy, 13 Hold, 7 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Cowen analyst Marc Bianchi raised the price target on Core Laboratories (NYSE: CLB) to $21.00 (from $20.00) while maintaining a Market Perform rating.
The analyst commented, "CLB outperformed the OIH by 85bps after a 1Q beat but weaker than expected FCF. International commentary remains positive with a growing list of new projects. While guided 2Q revenue growth appears robust, cost absorption relating to furlough program unwind weighs on incremental margins in the near to mid-term and therefore limits any positive revision to our estimates. Maintain Market Perform."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GXO Logistics Inc. (GXO) PT Raised to $72 at TD Cowen
- Pfizer (PFE) PT Raised to $40 at Argus
- Stanley Black & Decker (SWK) PT Raised to $135 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
